---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-158943"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:18:11.094795+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Apellis stockholders re-elect Gerald Chan and Cedric Francois as Class III directors

## Summary
- Gerald Chan received 82,568,712 votes for and 19,616,976 withheld (5,095,730 broker non-votes).
- Cedric Francois received 101,552,924 votes for and 632,764 withheld (5,095,730 broker non-votes).
- Stockholders ratified Deloitte & Touche as auditor for FY2023 (107,213,813 for, 39,783 against).
- Advisory vote on named executive officer compensation passed with 94,979,579 for, 6,659,652 against.

## SEC filing metadata
- accession: 0001193125-23-158943
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523158943/0001193125-23-158943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523158943/d470683d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-158943
- JSON: https://secwatch.observer/filing/0001193125-23-158943.json
- Plain text: https://secwatch.observer/filing/0001193125-23-158943.txt

## Key facts
- Shareholder Votes
  Apellis Pharmaceuticals, Inc. shareholders approved Election of class III directors at the 2023-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The stockholders of the Company elected Gerald Chan and Cedric Francois as class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2026. The results of the stockholders’ vote with respect to the election of the class III directors were as follows: Name For Withheld Broker Non-Votes Gerald Chan 82,568,712 19,616,976 5,095,730 Cedric Francois 101,552,924 632,764 5,095,730
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523158943/0001193125-23-158943-index.htm
- Shareholder Votes
  Apellis Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain Broker Non-Votes 107,213,813 39,783 27,822 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523158943/0001193125-23-158943-index.htm
- Shareholder Votes
  Apellis Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers (say-on-pay) at the 2023-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The stockholders of the Company approved the advisory vote on the compensation of the Company’s named executive officers. The results of the stockholders’ non-binding advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows: For Against Abstain Broker Non-Votes 94,979,579 6,659,652 546,457 5,095,730
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523158943/0001193125-23-158943-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.